catalog number :
MBS239121
products full name :
NATIVE MEASLES VIRUS
products short name :
MEASLES VIRUS
form :
Inactivated Pathogen. Inactivated Measles virus - liquid
concentration :
Total protein concentration 1.86 mg/ml.
storage stability :
Store at -70 degree C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Shelf Life: 18 months from date of despatch. Shipping: Ships with Dry Ice.
tested application :
ELISA (EIA)
other info1 :
Source: Measles virus, Edmonston strain, cultured in Vero cells. Preparation: Optimally infected cells are disrupted in culture fluids. The suspension is clarified and concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material. Instructions For Use: This item should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.
other info2 :
Buffer Solution: Minimum Essential Medium. Activity: This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately. Target Species: Viral. Preservative Stablizers: None Present. Approx. Protein Concentrations: Total protein concentration 1.86 mg/ml.
products description :
Native Measles Virus preparation contains a high concentration of virus and viral components. The preparation also contains some cellular material suspended in tissue culture medium. The Measles virus is a highly contagious single-stranded RNA virus that is mostly spread via the respiratory system. It may be passed via aerosol droplets from coughs or through contact with infected bodily fluids. It causes measles, a disease characterised by fever, cough, runny nose, red eyes and a rash. Most patients with uncomplicated measles will recover without antiviral treatment, however, some patients may develop diarrhoea, corneal ulceration, pneumonia or encephalitis. Complications are more likely in adults. In developed countries, most children are immunised against measles by the age of 18 months, as part of the three-part MMR (measles, mumps and rubella) vaccine.